

Fig. 6: New Drug Approvals 2013*

Brand	Company	Indication	Approval
Nesina	Takeda	Type 2 diabetes	Jan. 25
Kynamro	Genzyme	HoFH	Jan. 29
Pomalyst	Celgene	Multiple myeloma	Feb. 8
Kadcyla	Genentech	Breast cancer	Feb. 22
Osphena	Shionogi	Dyspareunia	Feb. 26
Lymphoseek	Navidea	Breast cancer, melanoma	Mar. 13
Dotarem	Guerbet	MRI	Mar. 20
Tecfidera	Biogen Idec	Multiple sclerosis	Mar. 27
Invokana	Janssen	Type 2 diabetes	Mar. 29
Breo Ellipta	GSK	COPD	May 10
Xofigo	Bayer	Prostate cancer	May 15
Tafinlar	GSK	Melanoma	May 29
Mekinist	GSK	Melanoma	May 29
Gilotrif	Boehringer Ingelheim	Lung cancer (NSCLC)	Jul. 12
Tivicay	ViiV	HIV-1 infection	Aug. 12
Beintellix	Takeda	Depressive disorder	Sep. 30
Duavee	Pfizer	Hot flashes, osteoporosis	Oct. 3
Adempas	Bayer	Pulmonary hypertension	Oct. 8
Opsumit	Actelion	PAH	Oct. 18
Vizamyl	GE Healthcare	Alzheimer's disease	Oct. 25
Gazyva	Genentech	Leukemia (CLL)	Nov. 1
Aptiom	Sunovion	Epilepsy	Nov. 8
Imbruvica	Pharmacyclics	Mantle cell lymphoma	Nov. 13
Luzu	Medicis	Antifungal	Nov. 14
Olysio	Janssen	Hepatitis C	Nov. 22
Sovaldi	Gilead	Hepatitis C	Dec. 6
Anoro Ellipta	GSK	COPD	Dec. 18

* NMEs and new biologics approved by FDA's Center for Drug Evaluation and Research (CDER)